

SUPPORTING MATERIAL

Figure S1: Flow-chart of the participants




Figure S2. Interaction between the FAIM2-rs7138803 polymorphism and adherence to the MedDiet in determining BMI (A) and heart rate (B).

Adjusted means depending on the strata of adherence to the Mediterranean diet (MedDiet) and the *FAIM2*-rs7138803. MedDiet was considered as dichotomous (low <9 points and high ≥ 9 points). Means were adjusted for sex, age, centre, type 2 diabetes, medications, smoking, drinking, physical activity and total energy intake. The model for the polymorphism was additive for BMI (n=7,161) and recessive for heart rate (n=6,937). P-values for the interaction terms were multivariable adjusted. Error bars: SE of means.





Figure S3. Stratified analysis of the association between the *FAIM2*-rs7138803 and diastolic blood pressure (DBP) (A) and heart rate (B) depending on hypertension.

Adjusted means depending on the hypertensive status diagnosed at baseline (yes or not) and the *FAIM2*-rs7138803. Means were adjusted for sex, age, centre, type 2 diabetes, medications, smoking, drinking, physical activity and total energy intake. The model for the polymorphism was additive for DBP (n=7,129) and recessive for heart rate (n=6,937). P-values for the interaction terms were multivariable adjusted. Multivariable adjusted P-values for the polymorphism in determining DBP were 0.089 and 0.036 in non-hypertensive subjects and hypertensive subjects, respectively. P-values for the polymorphism in determining heart rate in the same strata were 0.401 and 0.016, respectively. *P<0.017. Error bars: SE of means.



Supplemental Table 1: Demographic, lifestyle, clinical and biochemical characteristics of the participants depending on the *FAIM2*-rs7138803 polymorphism

Parameter	GG (n=3,019)		GA (n=3,235)		AA (n=907)		P ¹
	Mean	SD	Mean	SD	Mean	SD	
Age (years)	67.0 ± 6.2		66.9 (6.2)		66.9 (6.3)		0.528
Energy intake (kcal/d)	2274 ± 605		2276 ± 604		2275 ± 601		0.988
Total fat (% energy)	39.2 ± 6.8		39.2 ± 6.8		39.1 ± 6.5		0.963
Saturated fat (% energy)	10.0 ± 2.3		10.0 ± 2.2		10.0 ± 2.2		0.901
MUFA (% energy)	19.4 ± 4.6		19.4 ± 4.6		19.4 ± 4.3		0.511
Proteins (% energy)	16.6 ± 2.8		16.5 ± 2.8		16.6 ± 2.8		0.608
Carbohydrates (% energy)	41.9 ± 7.2		41.8 ± 7.2		41.9 ± 6.9		0.939
Adherence to the MedDiet	8.6 ± 2.0		8.7 ± 2.0		8.6 ± 2.0		0.447
Alcohol consumption (g/d)	8.4 ± 14.3		8.5 ± 14.1		8.2 ± 14.1		0.790
Physical activity (MET-min/day)	231 ± 232		235 ± 254		224 ± 211		0.447
Fasting glucose [^] (mg/dL)	121.0 ± 41.4		122.6 ± 41.5		122.9 ± 42.1		0.294
Total cholesterol [^] (mg/dL)	111.6 ± 38.4		110.8 ± 40.4		110.2 ± 38.2		0.575
LDL-C [^] (mg/dL)	130.8 ± 34.1		130.0 ± 35.9		129.7 ± 34.7		0.576
HDL-C [^] (mg/dL)	54.3 ± 14.5		53.4 ± 13.9		53.7 ± 13.3		0.068
Triglycerides [^] (mg/dL)	135.0 ± 75.9		139.2 ± 82.2		137.9 ± 76.3		0.133
Female sex : n, %	1761 (58.3)		1847 (57.1)		504 (55.6)		0.296
Type 2 diabetes: n, %	1436 (47.6)		1570 (48.5)		546 (50.3)		0.344
Hypertension: n, %	2492 (82.5)		2687 (83.1)		749 (84.6)		0.851
Dyslipidemia: n, %	2180 (72.2)		2346 (72.5)		646 (71.2)		0.743
Antihypertensive drugs: n, %	2195 (72.9)		2354 (72.8)		657 (72.4)		0.703
Lipid lowering drugs: n, %	1427 (47.3)		1581 (48.9)		441 (48.6)		0.354
Oral antidiabetic drugs: n;%	937 (31.0)		1026 (31.7)		322 (35.5)		0.141
Insulin: n, %	197 (6.5)		234 (7.2)		58 (6.4)		0.631
Current smokers: n, %	428 (14.2)		439 (13.6)		136 (15.0)		0.851

*: Values are means and standard deviations (SD) or n (%) or odds ratio, OR and 95% confidence intervals (95% CI)

¹: Unadjusted P values for mean comparison among genotypes

total energy intake, alcohol consumption, smoking and physical activity.

[^]: Fasting glucose, total cholesterol, LDL-C, HDL-C and triglycerides were obtained for n= 6317, n=6694, n=6612, n=6588, n=6622 subjects, respectively

Supplemental Table 2: Association between the *FAIM2*-rs7138803 polymorphism and categories of obesity. Prevalence and odds ratios (OR). Unadjusted and adjusted models

	<i>FAIM2</i> (G>A) Genotypes			Unadjusted ¹		Adjusted ²	
	GG (n=3,019)	GA (n=3,235)	AA (n=907)	OR* (95%CI)	P ¹	OR* (95%CI)	P ²
BMI<25 kg/m ² , (%)	45.8	42.1	12.1	1 (ref)		1 (ref)	
BMI: 25-30 kg/m ² , (%)	42.9	44.9	12.1	1.07 (0.93-1.22)	0.359	1.08 (0.94-1.23)	0.303
BMI: 30-35 kg/m ² , (%)	41.0	46.0	13.0	1.13 (0.99-1.29)	0.082	1.13 (0.99-1.30)	0.077
BMI ≥35 kg/m ² , (%)	39.9	45.4	14.6	1.19 (1.01-1.40)	0.043	1.20 (1.01-1.44)	0.046
P for trend		0.008					

Values are prevalences in %, odds ratio (OR) and 95% confidence intervals (CI)

OR: Odds ratio for the corresponding category of BMI in comparison with the reference category (BMI<25 kg/m²) for each variant allele (additive model)

¹: Unadjusted P values for the polymorphism (additive model)

²: Models adjusted for sex, age, center, type 2 diabetes, drinking, smoking, physical activity, adherence to Mediterranean diet and total energy intake.

Further adjustment for hypertension did not change the statistical significance of results

Supplemental Table 3. Association between the *FAIM2*-rs7138803 polymorphism and incidence of cardiovascular diseases in the whole population and by type 2 diabetes status. Hazard ratios (HR) and 95% confidence intervals (CI)

	Whole population	Type 2 diabetes status	
	(n=7,161)	Type 2 diabetics (n=3,462)	No-diabetics (n=3,699)
	HR 95% CI	HR 95% CI	HR 95% CI
Total cardiovascular events*			
<i>FAIM2 genotypes (Model 1)</i>			
G carriers	1.00 (ref.)	1.00 (ref.)	1.00 (ref.)
AA	1.18 (0.84-1.65)	1.08 (0.71-1.63)	1.35 (0.77-2.34)
	P ¹ =0.344	P ¹ =0.727	P ¹ =0.293
<i>FAIM2 genotypes (Model 2)</i>			
G carriers	1.00 (ref.)	1.00 (ref.)	1.00 (ref.)
AA	1.17 (0.83-1.62)	1.07 (0.79, 1.64)	1.34 (0.77-2.32)
	P ² =0.399	P ² =0.758	P ² =0.303
Myocardial Infarction			
<i>FAIM2 genotypes (Model 1)</i>			
G carriers	1.00 (ref.)	1.00 (ref.)	1.00 (ref.)
AA	1.60 (0.97-2.64)	1.83 (1.01-3.09)	1.21 (0.47-3.11)
	P ¹ =0.065	P ¹ =0.046	P ¹ =0.697
<i>FAIM2 genotypes (Model 2)</i>			
G carriers	1.00 (ref.)	1.00 (ref.)	1.00 (ref.)
AA	1.59 (0.97-2.63)	1.86 (1.03-3.37)	1.20 (0.46-3.09)
	P ² =0.068	P ² =0.041	P ² =0.710
Stroke			
<i>FAIM2 genotypes (Model 1)</i>			
G carriers	1.00 (ref.)	1.00 (ref.)	1.00 (ref.)
AA	1.01 (0.61-1.65)	0.89 (0.47-1.70)	1.30 (0.57, 2.85)
	P ¹ =0.981	P ¹ =0.680	P ¹ =0.563
<i>FAIM2 genotypes (Model 2)</i>			
G carriers	1.00 (ref.)	1.00 (ref.)	1.00 (ref.)
AA	0.98 (0.60-1.61)	0.87 (0.46-1.64)	1.24 (0.56-2.85)
	P ² =0.934	P ² =0.668	P ² =0.597

*Composite end point including myocardial infarction, stroke and cardiovascular mortality

Model 1: Adjusted for sex, age, center and dietary intervention groups

Model 2: Adjusted for sex, age, center, dietary intervention groups, BMI, medications, type 2 diabetes, alcohol, smoking, total energy intake and physical activity

P¹: P value obtained for the genotype effect (recessive model) of the polymorphism in the multivariable adjusted model 1. Cox regression models in the whole population or by type 2 diabetes

P²: P value obtained for the genotype effect (recessive model) of the polymorphism in the multivariable adjusted model 2. Cox regression models in the whole population or by type 2 diabetes

Additional adjustment of the models for hypertension (Model 3), did not change the statistical significance of the results

(P³: 0.069, 0.041 and 0.718 for the association between the *FAIM2* genotype and myocardial infarction in the whole population, in type 2 diabetic patients and in non-diabetic subjects, respectively)